文献速递肝病

直接抗丙型肝炎病毒药物的疗效改善肝移植术后早期生存并显著改变等待名单构成

The efficacy of direct anti-HCV drugs improves early post-liver transplant survival and induces significant changes in waiting list composition.
PubMed 文献 · J Hepatol · 2018-03-02

该研究评估了直接抗病毒药物(DAA)对西班牙加泰罗尼亚地区肝移植等待名单构成及移植后早期生存的影响。纳入2008年1月1日至2016年12月31日等待首次肝移植的1483例患者,按抗病毒治疗时期分为2008-2013年(以干扰素为基础治疗)和2014-2016年(DAA)两个时段。结果显示,HCV相关肝病等待名单入院比例从47%降至35%(p<0.001),NASH相关入院比例从4%升至7%(p=0.003);全队列移植后3年生存率从82%升至91%(p=0.002),抗-HCV阳性患者从76%升至91%(p=0.001),抗-HCV阴性患者无显著差异(88% vs 91%,p=0.359)。

要点

  • HCV相关肝病等待肝移植比例从2008-2013年的47%降至2014-2016年的35%(p<0.001)。
  • NASH相关等待名单入院比例从4%升至7%(p=0.003)。
  • 抗-HCV阳性患者移植后3年生存率从76%升至91%(p=0.001),抗-HCV阴性患者无显著差异。

核心结论

  • DAA的高疗效与肝移植等待名单构成的显著变化相关,并且改善了移植后生存。

研究设计与样本

  • 评估2008年1月1日至2016年12月31日在西班牙加泰罗尼亚地区等待首次肝移植的所有患者,共纳入1483例。
  • 按抗病毒治疗可及性分为两个时期:2008-2013年(以干扰素为基础的治疗)和2014-2016年(DAA治疗)。

主要发现

  • HCV相关肝病等待名单入院比例从2008-2013年的47%降至2014-2016年的35%(p<0.001),主要由于失代偿期肝硬化患者减少。
  • NASH相关等待名单入院比例从4%升至7%(p=0.003)。
  • 全队列移植后3年生存率在第二时期显著升高(82% vs 91%,p=0.002)。
  • 抗-HCV阳性患者移植后3年生存率从76%升至91%(p=0.001),抗-HCV阴性患者无显著差异(88% vs 91%,p=0.359)。
  • 全队列中,抗-HCV阳性血清学、2008-2013年时期和较高供者年龄与移植后死亡率独立相关;抗-HCV阳性受者中,时期和供者年龄与移植后死亡率独立相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: The efficacy of direct-acting antivirals (DAAs) has dramatically changed the prognosis of patients with chronic hepatitis C. We aimed to evaluate the impact of DAA therapy on the composition of the liver transplant (LT) waiting list and the early post-transplant survival. METHODS: We evaluated all patients admitted to the waiting list for a primary LT between 1st January 2008 and 31st of December 2016 in Catalonia, Spain. Time span was divided into two periods according to the availability of different antiviral therapies: 2008-2013 (interferon-based therapies) and 2014-2016 (DAA). Changes in the indications of LT and the aetiology of liver disease, as well as post-LT patient survival, were evaluated according to the year of inclusion and transplantation, respectively. RESULTS: We included 1,483 patients. Admissions in the waiting list for hepatitis C virus (HCV)-related liver disease decreased significantly, from 47% in 2008-2013 to 35% in 2014-2016 (p <0.001), particularly because of a reduction in patients with decompensated cirrhosis. In contrast, NASH-related inclusions increased from 4% to 7% (p = 0.003). Three-year post-LT patient survival increased significantly in the second period in the whole cohort (82% vs. 91%, p = 0.002), because of better survival in anti-HCV positive patients (76% vs. 91%, p = 0.001), but not in anti-HCV negative patients (88% vs. 91% p = 0.359). Anti-HCV positive serology, the time period of 2008-2013 and higher donor age were independently associated with post-LT mortality in the whole cohort; while time period and donor age were independently associated with post-LT mortality in anti-HCV positive recipients. CONCLUSIONS: The high efficacy of DAAs is associated with significant changes in the composition of the LT waiting list and, more importantly, results in improved post-transplant survival. LAY SUMMARY: The efficacy of the new direct-acting antivirals is associated with a significant improvement in survival of patients undergoing liver transplantation because of hepatitis C virus-related liver disease. In addition, it has decreased the number of patients with hepatitis C that need a liver transplant.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Crespo G, Trota N, Londoño MC, et al. The efficacy of direct anti-HCV drugs improves early post-liver transplant survival and induces significant changes in waiting list composition. J Hepatol. 2018. PMID: 29481821. doi:10.1016/j.jhep.2018.02.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。